
Searching for new TCR targets, immunotherapy startup emerges with Stanford tech, $40M round
In the last decade, immunotherapy, which involves the usage of a patient’s own immune cells to fight cancers, has gained great momentum. In one variation, the treatment involves removing a patient’s T cells, a type of white blood cell, and enabling them to recognize proteins that are only present in cancer cells. Upon finding its nemesis the T cells attack the cancer cells. But the major challenge researchers face is discovering more and more of these proteins that are displayed specifically on cancer cells, said Stefan Scherer, CEO of 3T Biosciences, a San Francisco-based biotech.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.